Showing results (21-30 of 124) with videos related to
Sort By:
Pageof 13
Continuum (Minneapolis, Minn.)|August 7, 2013
Diagnosis and differential diagnosis of multiple sclerosisIlana B Katz Sand, Fred D LublinMultiple Sclerosis (Houndmills, Basingstoke, England)|June 15, 2023
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)Kyle Smoot, Horia Marginean, Tiffany Gervasi-Follmar, et al.Journal of Rehabilitation Research and Development|June 8, 2002
Immunotherapy of multiple sclerosis--current practice and future directionsMark J Tullman, Fred D Lublin, Aaron E MillerClinical Therapeutics|November 25, 2018
Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational StudyKiren Kresa-Reahl, Pavle Repovic, Derrick Robertson, et al.Neurology|October 27, 2020
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple SclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.European Journal of Neurology|January 15, 2021
Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?Marcus W Koch, Jop Mostert, Pavle Repovic, et al.Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|August 2, 2003
Magnetic resonance imaging of meningoradiculomyelitis in early disseminated Lyme diseaseMark J Tullman, Bradley N Delman, Fred D Lublin, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2021
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 30, 2021
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MSMarcus W Koch, Jop Mostert, Pavle Repovic, et al.Journal of Neurology|August 15, 2021
Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial datasetMarcus W Koch, Jop Mostert, Pavle Repovic, et al.Pageof 13